Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

What to look forward to in GaBI Journal, 2017, Issue 2 / Professor Philip D Walson, MD, USA/Germany

Editorial

Trends and challenges in biosimilars pricing and reimbursement policies in Europe and beyond / Alessandro Curto, MSSc, Italy

Commentary

Strategies for pricing of pharmaceuticals and generics in developing countries / Brian Godman, BSc, PhD; Professor Mohamed Azmi Hassali, PhD

Patent expiry and costs for anticancer medicines for clinical use / Brian Godman, BSc, PhD; Claudia Wild, PhD; Alan Haycox, PhD

Current overview of biosimilars in Iran / Hamideh Aghajani-Lazarjani, PhD; Fereidoun Mahboudi, PhD, Iran

Original Research

What pricing and reimbursement policies to use for off-patent biologicals in Europe? – Results from the second EBE biological medicines policy survey / Jean-Baptiste Reiland, MSc; Barbara Freischem; Alexander Roediger, MA

Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey / Sabine Vogler, PhD; Peter Schneider, MA

Bioequivalence study of two formulations of 60 mg daclatasivir in healthy volunteers / Sattam Turky AlGhodyyr, MSc;  Mohammad Khalil Mohammad, RPh., PhD; Sanabel Omar Dawabsheh; Mohammad Ali Abu Fara, MD; Majdi Naser Abu Al hajj; Rabab Fayyez Tayyem, PhD

Assessment of medicine quality in emerging markets: the changing face of inferior medicines over time / Roger Bate, USA; Lorraine Mooney, UK

The assessment of biosimilarity with SABE and IBE criteria under a switching/alternating design / Aijing Zhang, PhD; Associate Professor Jung-Ying Tzeng; Professor Shein-Chung Chow, PhD, USA (Biosimilarity and Interchangeability)

Review Article

Roundtable on registries: practical considerations for registries – making them work, London, UK, 26 January 2017

A survey of Australian prescribers’ views on the naming and labelling of biologicals / Stephen P Murby, FRSA; Michael Reilly, Esq

Real world data about biosimilars: results from an Italian distributed network / Gianluca Trifirò; Ylenia Ingrasciotta; Ilaria Marcianò; Armando Genazzani

Generic immonusuppressants comparability studies / Marc Maliepaard, PhD; Professor Hubert G M Leufkens, PharmD, PhD, The Netherlands (Generic Immunosuppressants in Transplantation)

Opinion

Generic immunosuppression in transplantation: a controversial analysis / Jacques Rottembourg, MD

Meeting Report

Pharmacovigilance, traceability and building trust in biosimilar medicines

Value added medicines: how repurposed medicines bring value to patients and pharmacists

Special Report

Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and USA / Subramanian Venkatesan, MSc; Martine Lamfers, PhD; Sieger Leenstra, MD, PhD; Arnold G. Vulto, PharmD, PhD, FCP

Interchangeability of biosimilars in the US and around the world / Michelle Derbyshire, PhD, GaBI Online Editor

Abstracted Scientific Content

Generic prices estimated for four novel cancer drugs / Eleanor Bird, GaBI Journal Editor

Effective generics substitution / Maysoon Delahunty, GaBI Journal Editor

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL: http://gabi-journal.net/gabi-journal/forthcoming-issue


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048